Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

SAN DIEGO, Oct. 8, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET.  

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus (EBV)-positive lymphomas. Viracta is pursuing application of this kick and kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma and gastric carcinoma, and other viral-related cancers.

For additional information please visit www.viracta.com.

Media and Investor Contact:

Amy Conrad
Juniper Point
amy@juniper-point.com 
858-366-3243

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com 
(212) 915-2569

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-solebury-trout-fall-private-company-showcase-2020-301148988.html

SOURCE Viracta Therapeutics, Inc.